SELLAS Life Sciences Group Inc
SLSHealthcare|Biotechnology|USA
$12.76
-0.74 (-5.52%)
Tangible Book
$0.58
Earnings Power
$6.03
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04229979 Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 | Acute Myeloid Leukemia | P3 | Active | 127 | RCT, Open-label | Galinpepimut-S, Azacitidine, Venetoclax, Decitabine, Cytarabine, GM-CSF |
| NCT04588922 Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | Hematologic Malignancies | P1P2 | Recruiting | 160 | RCT, Open-label | SLS009, venetoclax, azacitidine |
| NCT01570036 Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax | Breast Cancer | P2 | Completed | 275 | RCT, Single-blind | Herceptin, NeuVax vaccine, GM-CSF |
| NCT02297698 Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients | Breast Cancer | P2 | Completed | 100 | RCT, Single-blind | NeuVax vaccine, Trastuzumab, GM-CSF |
| NCT01827137 WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | Multiple Myeloma | P1P2 | Completed | 20 | Open-label | Galinpepimut-S, GM-CSF, lenalidomide, bortezomib |
| NCT03761914 Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Acute Myelogenous Leukemia, Ovarian Cancer | P1P2 | Completed | 26 | Open-label | galinpepimut-S, pembrolizumab, GM-CSF |
| NCT01266083 WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | P2 | Completed | 22 | Open-label | Galinpepimut-S, GM-CSF |
| NCT01265433 Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy | Malignant Pleural Mesothelioma | P2 | Completed | 41 | RCT, Double-blind | Galinpepimut-S + Montanide + GM-CSF, Montanide + GM-CSF |
| NCT05593185 Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS | Acute Myeloid Leukemia, Myelodysplastic Syndromes | AVAILABLE | — | — | Galinpepimut-S |